Twist Bioscience's business model is highly differentiated through its proprietary, scalable DNA synthesis technology and automation, supporting strong growth and margin expansion. The platform's defensibility is reinforced by manufacturing scale, cost leadership, and integration into AI-driven wor…
Twist Bioscience (TWST) Q3 2026: AI-Enabled Discovery Orders Set to Double Again as Platform Scale Deepens
Twist Bioscience delivered its 14th consecutive quarter of growth, propelled by surging demand for AI-enabled drug discovery and next-generation sequencing (NGS) applications. The company’s silicon-based DNA synthesis platform is translating digital biology trends into durable commercial expansion, with management signaling repeat triple-digit AI order growth into 2027. Margin gains and operational leverage are emerging as scale, automation, and new product introductions reinforce Twist’s competitive moat.
Summary
- AI-Driven Order Momentum: Repeat triple-digit AI discovery order growth is expected into 2027, signaling robust, sticky demand.
- Manufacturing Scale Advantage: Platform automation and cost discipline are driving margin expansion and operational resilience.
- Visibility into Profitability: Path to sustained EBITDA breakeven is underpinned by broad-based customer growth and product mix shift.
Business Overview
Twist Bioscience is a synthetic biology company specializing in semiconductor-based DNA synthesis, enabling customers to design, build, and test genetic sequences at scale. Revenue is generated from two main segments: DNA Synthesis and Protein Solutions (DSPS), which serves therapeutics and industrial customers, and NGS Applications, which powers diagnostics and research. The company’s technology underpins drug discovery, diagnostics, academic research, and industrial biotech, with a growing footprint in AI-enabled workflows.
Performance Analysis
Twist reported record quarterly revenue, up 23% year-over-year, marking its 14th straight quarter of sequential growth. Growth was broad-based: DSPS revenue jumped 39% year-over-year, driven by a 49% surge in therapeutics, while NGS Applications grew 12% with strong diagnostic customer adoption. Gross margin improved to 52.8%, with 70% of incremental revenue dropping to the gross line, reflecting manufacturing leverage and product mix optimization.
Geographically, Americas led with 30% growth, while EMEA and APAC posted 9% and 26% gains, respectively. Academic and government revenue rebounded sharply, up 32% year-over-year and 21% sequentially, as large U.S. customers returned. Operating expenses included one-time transition costs, but management projects over $5 million in OPEX reduction in Q4, supporting the EBITDA breakeven trajectory.
- AI Discovery Acceleration: Orders for AI-enabled drug discovery are set to double again in fiscal 2027, following a similar leap in 2026.
- Diagnostics Engine: NGS Applications revenue growth is anchored by top diagnostic accounts and new product launches, with 48% of NGS revenue from the top 10 customers.
- Cost Structure Leverage: Manufacturing improvements have reduced costs by 60% and turnaround times by 73% over three years, strengthening the margin profile.
Twist’s ability to convert scientific innovation into commercial growth is evident in its expanding customer base, repeat business, and rising gross margin. The company’s operational discipline is translating into improved profitability and sets the stage for continued outperformance.
Executive Commentary
"Our funnel of opportunities continues to expand meaningfully, and we believe that we have the potential to again post triple-digit percentage order growth for AI-enabled rediscovery in fiscal 2027 when compared to fiscal 2026."
Dr. Emily Leproust, CEO and Co-founder
"Over the last three years alone, we've reduced manufacturing costs by 60%, reduced waste by 70%, reduced turnaround time by roughly 73%, and increased oligonucleotide capacity fourfold. Those gains improve our economics, strengthen our competitive position, and create additional capacity to support future growth."
Dr. Patrick Finn, President and COO
Strategic Positioning
1. AI-Enabled Drug Discovery as a Durable Growth Engine
AI-enabled discovery now represents a core, recurring revenue driver, with large pharma, biotech, and tech customers integrating Twist’s platform into their design-build-test-learn cycles. Management guided to repeat triple-digit order growth in AI for both 2026 and 2027, reflecting robust pipeline visibility and deepening customer engagement.
2. Platform Scale and Automation Drive Defensible Moat
Twist’s semiconductor-based DNA synthesis platform, coupled with automation and proprietary software, delivers structural advantages in cost, scale, and speed. Continuous improvements in manufacturing efficiency and productization enable rapid new product launches and high throughput, making the platform difficult to replicate for competitors.
3. Customer Diversification and Product Mix Expansion
Growth is broadening across therapeutics, diagnostics, and academic/government segments. NGS Applications are benefiting from new diagnostic assays and tumor-informed molecular residual disease (MRD) workflows. Complex genes and data characterization services are expanding wallet share with existing customers and attracting new entrants.
4. Commercial and Operational Execution
Twist’s focus on operational excellence is visible in its OPEX discipline, cost reduction initiatives, and rapid scaling of new offerings. Early access launches, such as complex genes, have quickly transitioned to commercial scale, reinforcing the company’s ability to operationalize innovation.
Key Considerations
This quarter reinforced Twist’s position as an enabling platform at the intersection of digital biology and synthetic genomics, with AI adoption catalyzing higher order volumes and customer stickiness.
Key Considerations:
- AI-Driven Demand Expansion: Repeat business and new customer wins in AI-enabled drug discovery are creating a high-visibility revenue runway.
- Margin Expansion from Automation: Significant cost and turnaround time reductions are supporting gross margin gains and future scalability.
- Product Portfolio Diversification: New offerings in complex genes, proprietary enzymes, and data characterization are deepening customer engagement and broadening addressable market.
- Academic and Government Rebound: Strong sequential recovery in these segments demonstrates business resilience and effective execution in budget-constrained environments.
Risks
Competitive intensity remains a watchpoint, with rivals investing in alternative DNA synthesis and data services, though Twist’s scale and automation are currently differentiating. Order patterns, especially in academic/government and emerging markets, can be volatile, and the company’s ability to sustain margin gains hinges on continued volume growth and operational discipline. Execution risk around rapid new product introductions and maintaining EBITDA breakeven as investment continues is also notable.
Forward Outlook
For Q4 2026, Twist guided to:
- Total revenue of $123 to $124 million, up approximately 25% year-over-year
- Sequential growth in both DSPS and NGS Applications segments
For full-year 2026, management raised guidance to:
- Total revenue of $456 to $457 million, an increase of $12 million at the midpoint
Management highlighted several factors that support sustained growth:
- Visibility into repeat triple-digit AI-enabled discovery order growth in 2027
- Expectation of gross margin above 52% for fiscal 2026, with a long-term target above 60%
Takeaways
Twist’s platform scale, automation, and customer adoption are translating into durable revenue growth, margin expansion, and a credible path to profitability.
- AI Demand as a Structural Tailwind: The shift to AI-driven drug discovery is not just cyclical but structural, with customers moving from model-building to scaled, iterative experimentation, driving sustained order growth.
- Margin and Cash Flow Inflection: Manufacturing cost reductions and OPEX discipline are supporting the transition to EBITDA breakeven, even as investments in capacity and product innovation continue.
- Watch for New Product and Service Penetration: Expanding capabilities in data characterization and proprietary enzymes will be key to wallet share and future margin upside.
Conclusion
Twist Bioscience’s Q3 2026 results confirm its emergence as a platform leader in synthetic biology, with AI-enabled drug discovery and NGS driving robust growth and margin improvement. Operational discipline and expanding product breadth position the company for continued outperformance, though competitive and execution risks warrant ongoing attention.
Industry Read-Through
Twist’s results underscore a major inflection in life sciences, where AI-driven workflows are accelerating demand for scalable, automated DNA synthesis and data services. Competitors in synthetic biology and genomics must contend with rising customer expectations for speed, scale, and integrated data solutions. The operational leverage and margin gains Twist is achieving through automation set a new bar for cost structure in the sector, challenging emerging and incumbent players alike. Diagnostic and research tool providers should note the growing importance of end-to-end platforms that enable rapid iteration and data-rich experimentation, as well as the stickiness created by integration into AI-driven workflows.